| December 1, 2022 | | | By Order of the Board of Directors | |
| | | |
/s/ Joel Shulman
Joel Shulman
Chairman and Chief Executive Officer |
|
| December 1, 2022 | | | By Order of the Board of Directors | |
| | | |
/s/ Joel Shulman
Joel Shulman
Chairman and Chief Executive Officer |
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 20 | | | |
| | | | 26 | | | |
| | | | 27 | | | |
| | | | 28 | | | |
| | | | 32 | | | |
| | | | 40 | | | |
| | | | 42 | | | |
| | | | 44 | | | |
| | | | 44 | | | |
| | | | 44 | | | |
| | | | A-1 | | |
Name
|
| |
Age
|
| |
Position
|
|
Dr. Joel Shulman | | |
55
|
| | Chairman and Chief Executive Officer | |
Eva Adosoglou | | |
31
|
| | Chief Operating Officer | |
Grant Grigorian | | |
59
|
| | Chief Financial Officer | |
Kevin Cramton | | |
61
|
| | Director | |
Charles Aggouras | | |
55
|
| | Director | |
Jeffrey Mortimer | | |
57
|
| | Director | |
| | |
Class A Common Stock
|
| |
Class B Common Stock
|
| |
Approximate
Percentage of Outstanding Common Stock |
| |||||||||||||||||||||
Name and Address of Beneficial Owner(1)
|
| |
Number of
Shares Beneficially Owned |
| |
Approximate
Percentage of Class |
| |
Number of
Shares Beneficially Owned |
| |
Approximate
Percentage of Class |
| ||||||||||||||||||
Apeiron Capital Sponsor, LLC(2)
|
| | | | — | | | | | | — | | | | | | 4,312,500 | | | | | | 100% | | | | | | 20% | | |
Joel Shulman(3)
|
| | | | — | | | | | | — | | | | | | 4,312,500 | | | | | | 100% | | | | | | 20% | | |
Eva Adosoglou(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Grant Grigorian(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Kevin Cramton(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Charles Aggouras(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Jeffrey Mortimer(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
All executive officers and directors as a group
(six individuals) |
| | | | — | | | | | | — | | | | | | 4,312,500 | | | | | | 100% | | | | | | 20% | | |
Other 5% Stockholders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Highbridge Capital Management, LLC(4)
|
| | | | 1,179,474 | | | | | | 6.84% | | | | | | — | | | | | | — | | | | | | 5.5% | | |
Calamos Market Neutral Income Fund(5)
|
| | | | 1,000,000 | | | | | | 5.8% | | | | | | — | | | | | | — | | | | | | 4.6% | | |
Saba Capital Management L.P.(6)
|
| | | | 1,300,000 | | | | | | 7.5% | | | | | | — | | | | | | — | | | | | | 6.0% | | |
| | | | APEIRON CAPITAL INVESTMENT CORP. | |
| | | |
By:
|
|
| | | | Name: Dr. Joel Shulman | |
| | | | Title: Chief Executive Officer | |
D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#044%]@8&!A8&)P8W!D@&
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M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z& 105E!MI79V='8$?I3<^%]#'B9CMUUXZ?<6T,NX+<26(F@DF3:"#)%
M'*8#N8,('EPI3[0XD!GYC?\ !.?_ )*#\6/^P^O_ *6:K0(X'_@HFZ_%*SU?
M5K9=7_M+PI<6W_"/SZ?97KVRM"T O3_"WXBWGAZ*WU"72]3UNZUNVU:_:34+FWLK5;"_L[FUL].1=.
MG<6[0VBH_F[7CG>6X+732-0!]6>*/ UG\5]#DTCQ+96\\%[;JE[:!VEA#$!F
M$&VU:\BL=/
MNGTC5(K6XNI9&B2&.YDM%@+EU=3\X"E'W$!&( -#PO\ MB^"O%_B./PC;7UP
MFO2[MMA/%$\=Y/;16L:
MAMAD-R ?7G[.WA&+XG:^_BW2K_Q7I^CZ3>:AIB:7J>H:A-!J7]_>Z?'(ZR*SBQN[F:TW_ +Z4
MAC$2KNS@ASNH W_C;^R9X-_:,N+>Z\4V$E_):QM';@WMY#'&K-N
&VU:\BL=/NGTC5(K6XNI9&B2&.YDM
M%@+EU=3\X"E'W$!&( -#PO\ MB^"O%_B./PC;7UPFO2[MMAWN=3;4KXJ
M\=G-;303LLEA))+<3")TN=SJ X$ZNWFF"$ ^N_V=/">L_#_PMIFB:W%9QW.E
MV=K8JUG